Ribogene to Appear at the Wall Street Forum Boston Conference June 3

Hayward, California, UNITED STATES

HAYWARD, Calif., May 28, 1999 (PRIMEZONE) -- RiboGene Inc. (AMEX: RBO), a biotechnology company focused on the discovery and development of novel therapeutics for the treatment of infectious diseases announced today that its CEO, Charles J. Casamento, will be making an analyst presentation at the Wall Street Forum in Boston on June 3, 1999 at 8:50 am, eastern time.

The presentation is being conducted in forum of analysts in Boston with the simultaneous attendance of institutions globally via Wall Street Forum's Web site at www.wallstreetforum.com. Using a PC and this website, viewers will hear RiboGene's CEO present live while simultaneously viewing both its corporate slide presentation and CEO at the podium. Internet attendees are encouraged to participate in the live question and answer session and have up to 90 days post-meeting to access the retrievable presentation. An informal break-out session will follow the live global webcast. Analysts, portfolio managers and media representatives are invited to attend, either in person or via the Internet.

RiboGene, Inc. (AMEX: RBO) of Hayward, CA is a biotechnology company focused on the discovery and the development of novel therapeutics for the treatment of infectious diseases. The Company's drug discovery efforts target bacterial, fungal and viral infections, for which the efficacy of existing therapies is being threatened by the emergence of drug resistance or for which existing therapies have had limited effectiveness. RiboGene has strategic alliances with Dainippon Pharmaceutical Co., Ltd., Roberts Pharmaceutical Corporation, ArQule, Inc., and EnzyMed, Inc. As a means to provide near-term revenues and expedite the commercialization of the Company, RiboGene in-licensed Emitasol(R) (intranasal metaclopramide) for the treatment of diabetic gastroparesis and for the treatment of nausea and vomiting in the cancer chemotherapy patient, which it is developing in partnership with Roberts Pharmaceutical Corporation. Emitasol (R) is expected to begin Phase III human trials in 1999. The product has recently been introduced in Italy and is pending approval in 6 other European countries.

If you are interested in attending, please RSVP to The Wall Street Forum at 617-523-1234 or register on-line at www.wallstreetforum.com. If you would like further information on RiboGene, then please visit their website at www.rigogene.com, or contact Alan Stone & Company at 310-444-3940 or via e-mail at a_stone@alanstone,com for an investor relations package.


Note: Except for the historical information contained herein this press release contains forward-looking statements that involve risks and uncertainties, which are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1998, as filed the Company with the Securities and Exchange Commission. The risk factors and other information contained in such Annual Report should be considered in evaluating the Company's prospects and future financial performance.


Contact Data